CNR Research announced that it has entered into a conditional exclusive partnership with Equilab International, an Indonesian clinical trial contract research organization, for close collaboration and joint project implementation.
Through this agreement, the two companies will prioritize linking clinical trials commissioned in Korea and Indonesia as a mutually beneficial channel, establishing a strategic collaborative structure with an operational system comparable to a single organization. Based on this, the two companies plan to enhance the execution capacity and operational efficiency of clinical trials conducted in both countries.
The two companies will establish a foundation for joint development, focusing specifically on clinical trials for approval conducted simultaneously in Korea and Indonesia. With multiple Phase 3 clinical trials planned, the goal is to shorten the approval process and improve operational quality by establishing a collaborative system from the early stages of clinical trials.
Collaboration will be conducted across all stages of clinical trials, from clinical trial design to regulatory compliance, trial site operation, and monitoring. The scope of collaboration will expand to large-scale Phase 3 clinical trials, focusing on essential chronic disease treatments, thereby simultaneously enhancing the efficiency and cost-effectiveness of subject recruitment.
Equilab, Indonesia's first and largest CRO, provides clinical trial operations and central laboratory analysis services that meet international standards. This has secured its competitive edge in the global clinical trial market.
Through this agreement, CNR Research plans to strengthen its clinical trial performance capabilities in Indonesia, a major Southeast Asian clinical trial market, by leveraging local expertise, and expand its capacity to respond to multinational clinical trials.
- See more related articles
You must be logged in to post a comment.